

2nd International Conference on

Eye and Vision

September 26-28, 2016 Orlando, USA

Recent advancements and future opportunities for sustained ocular drug delivery systems

Viral Kansara

Novartis Institutes for Biomedical Research, Inc., USA

The field of sustained ocular drug delivery has seen remarkable innovations in the last decade. Many ocular blinding diseases require a chronic, in some cases lifelong treatment, and hence an unmet medical need for sustained ocular delivery technologies is becoming more evident. Recent advancements in novel drug delivery technologies have opened a new avenue in the field of sustained ophthalmic products. An integrative ocular drug delivery approach involving discovery scientists, pharmacologists, polymer chemists, clinicians, toxicologists and regulatory agencies is a paramount to the success of the sustained ocular delivery system. This talk will focus on key barriers and factors affecting ocular drug delivery, and strategies to overcome these barriers. Various routes of ocular drug administration and challenges associated with current strategies will be discussed in details. Key pharmacokinetic principles and pharmacological considerations for developing successful sustained ocular delivery products will be presented. Recent advancements and future opportunities and a few success stories in the field of sustained drug delivery to the eye will also be discussed.

Biography

Viral Kansara is Investigator and Head of Ocular Pharmacology and Drug Delivery Laboratory in the Ophthalmology department at Novartis Institutes for Biomedical Research, Inc. He has over 10 years of combined industry and academia experience and expertise in the field of "Ocular drug discovery, delivery and drug development". At Novartis, his lab focuses on "The discovery and development of novel treatment therapies" for blinding diseases such as macular degeneration, diabetic retinopathy and glaucoma.

viral.kansara@novartis.com**Notes:**